





**Figure S1. Flow cytometry analysis of BAL cells: gating strategy.** After exclusion of doublets and debris, a sequential gating strategy was then employed to first identify populations expressing specific markers: CD3<sup>+</sup>/CD4<sup>+</sup> and CD3<sup>+</sup>/CD8<sup>+</sup> T cells. Tregs (CD3<sup>+</sup>/CD4<sup>+</sup>/CD25<sup>+</sup>/CD147<sup>-</sup>). HLA-DR<sup>+</sup> cells were subdivided into alveolar macrophages (high side scatter CD163<sup>+</sup>/CD206<sup>+</sup> (M<sub>2c</sub>), CD163<sub>lo</sub>/CD206<sup>+</sup> (M<sub>2a</sub>) and CD163<sub>lo</sub>/CD206<sub>lo</sub> (M<sub>1</sub>)) and monocytes (HLA-DR<sup>+</sup> low side scatter) were classified as resident (CD14<sup>+</sup>/CD16<sup>+</sup>) and recruited (CD14<sup>+</sup>/CD16<sup>-</sup>). Neutrophils (HLA-DR<sup>-</sup>/CD16<sup>+</sup>), B cells (HLA-DR<sup>-</sup>/CD19<sup>+</sup>), NK (CD56<sup>+</sup>/CD3<sup>-</sup>), NKT cells (CD56<sup>+</sup>/CD3<sup>+</sup>).



**Figure S2. Flow cytometry analysis of BAL cells: Alveolar macrophage gating strategy.** a) Representative alveolar macrophage gating strategy in a single patient pre-dose at day-1 and at day 14 at 2 h post-dose following 10 mg TD139 administration for 14 days. HLA-DR<sup>+</sup> macrophages were classified as M<sub>1</sub>, M<sub>2a</sub> or M<sub>2c</sub> based on CD206 and CD163 expression. Histograms show Galectin-3 expression on the different subsets M<sub>2a</sub> pink, M<sub>2c</sub> blue and M<sub>1</sub> orange on day -1 and day 14. b) % change in prevalence of M<sub>2a</sub> and M<sub>2c</sub> subsets from day -1 to day 14 in the different dose groups.



**Figure S3. Galectin-3 changes in alveolar macrophages.** Absolute change in surface macrophage galectin-3 on day -1 pre-dose or at 2 h post-administration of placebo, 0.3 mg, 3 mg and 10 mg of TD139 on day 14. AM, alveolar macrophages; MFI, mean fluorescence intensity.



**Figure S4. Flow cytometric analysis of immune cells in BAL.** Cell types in BAL were identified as described in supplemental methods and outlined in figure S1. Results represent mean  $\pm$  SEM from day -1 and day 14 samples from placebo and 0.3 mg, 3 mg and 10 mg TD139 groups.